Xcout Intel
InteRNA Technologies competitors & alternatives
The 12 closest competitors and alternatives to InteRNA Technologies among biotechnology companies — ranked by similarity to what InteRNA Technologies actually does, not by market-cap band.
Subscribe to see InteRNA Technologies’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About InteRNA Technologies
InteRNA Technologies is a venture-backed biotech and life sciences company founded in 2008 and headquartered in Utrecht, Netherlands. The company specializes in the development of microRNA (miRNA)-focused drug pipelines and therapeutics. It operates within the biopharmaceutical sector, supported by various institutional backers and investors.
InteRNA Technologies at a glance
InteRNA Technologies is a biotechnology company headquartered in Netherlands. Xcout tracks 10 named people at InteRNA Technologies, including Yuval Gottenstein (CEO).
InteRNA Technologies leadership
- Yuval GottensteinCEO
- Roger D. KornbergScientific President
- Guy KornbergCOO
- Etty Genis BarakCFO
- Joel Van GelderChief Innovation Officer
- Jacob GottensteinCo-founder
4 more named people on record for InteRNA Technologies, with roles, board committees and tenure — see the full roster →
Top 12 InteRNA Technologies competitors
Ranked by semantic similarity — how close each company is to InteRNA Technologies by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Similar biotechnology company
Atalanta Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, focused on developing RNA-interference therapeutic interventions for neurodegenerative diseases. The company launched with significant venture backing from life sciences investors.
Similar biotechnology company
miRecule, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, focused on developing RNA therapeutics.
Similar biotechnology company
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.
Similar biotechnology company
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Similar biotechnology company
Aptadir Therapeutics is a biotechnology company based in Milan, Italy, specializing in the development of RNA inhibitor-based therapeutics. The firm focuses on creating novel treatments for intractable cancers and genetic disorders.
Similar biotechnology company
Inthera Bioscience AG is a Swiss biotechnology company focused on the discovery and development of targeted small molecule therapies, including modulators of intracellular protein-protein interactions, for the treatment of solid tumors. Headquartered in Zurich, the private company's pipeline features assets such as its lead oral small molecule candidate, INTH-454.
Biotech
Orna Therapeutics Inc. is a biotechnology research company headquartered in Watertown, Massachusetts. The firm employs between 51 and 200 people and focuses on life-sciences and advanced therapeutic developments.
Similar biotechnology company
Enthera is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Milan, Italy. The company focuses on developing first-in-class therapeutics for auto-immune disorders and is backed by investors such as Sofinnova Partners and BiovelocITA.
Similar biotechnology company
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Similar biotechnology company
Argonaute RNA is a therapeutics company headquartered in Bristol, United Kingdom, pursuing opportunities in RNA-based treatments.
Biotech
Neumirna Therapeutics is a biotechnology company founded in 2021 and headquartered in Copenhagen, Denmark. The firm is dedicated to pioneering RNA-based therapies to treat epilepsy, Parkinson's disease, and other neurological disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of InteRNA Technologies and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for InteRNA Technologiesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →